Good MorningEquities pulled back again on Tuesday following another round of hotter than expected inflation data. The PPI came in at 0.8% for the month, up 0.2% from October and 0.3% hotter than forecast. The figure is coupled with high core readings and the hottest YOY increases on record.
If there was any doubt the FOMC would be raising interest rates sooner than expected this news should lay those doubts to rest. The CME Fedwatch tool is pricing in a near 60% chance the first hike will come by May and a 70% chance for two .25% interest rate hikes by June so today’s FOMC meeting is more important than ever. The Fed is expected to accelerate the taper and move the timeline for rate hikes forward.
Featured: 5 Best Stocks Under $5 to Buy Now (Ad) 
|
Markets | | There are several reasons why companies and employees are reconsidering return-to-work plans. In this article, we give you three quality remote work stocks that have significant upside heading into 2022. Read the Full Story |
|
From Our Partners2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines.
But even in uncertain times, innovation doesn’t slow down.
In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles.
Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar. | | 👉[Click here to access your FREE AI stocks report now.] |
|
Markets | | Casino operator Las Vegas Sands (NYSE: LVS) stock has fallen down to its COVID-19 low levels in recent weeks. The epicenter stock has seen renewed fears of China intervention with the Macau gambling industry as well as COVID-19 protocols tightening again. Gambling is one of the few industries that d... Read the Full Story |
|
Markets | |
3 Low-Volatility Stocks Showing Strength in a Weak Market
Market sentiment can change in the blink of an eye, and that’s quite evident in the recent selling pressure we’ve seen occurring in the high growth areas. A lot of this likely has to do with the upcoming Federal Reserve meeting... Read the Full Story |
|
|
Tech | |
Since the early days of the pandemic, the reopening trade has been a popular way play the anticipated turnaround in beaten up, economically sensitive stocks.
Some groups like restaurants and retailers have recovered much if not all of their 2020 losses. Others like airlines and hotels have many m... Read the Full Story |
|
Markets | | Greenpeace on Wednesday renewed calls against proposed deep-sea oil and gas exploration off southwest Greece, warning of “unbearable” consequences to endangered Mediterranean whales and dolphins.
Greenpeace Greece official Kostis Grimanis said the project should be scrapped before “it... Read the Full Story |
|
|
Markets | | The luxury fashion house Chanel has chosen Leena Nair, an industry outsider from India and longtime executive at Unilever, to be its new CEO.
Nair said in a Twitter post that she was “humbled and honored to be appointed the Global Chief Executive Officer of @CHANEL, an iconic and adm... Read the Full Story |
|
Markets | | The luxury fashion house Chanel has chosen Leena Nair, an industry outsider from India and longtime executive at Unilever, to be its new CEO.
Nair said in a Twitter post that she was “humbled and honored to be appointed the Global Chief Executive Officer of @CHANEL, an iconic and adm... Read the Full Story |
|
Politics | | The omicron variant is offering more hints about what it may have in store as it spreads around the globe: A highly transmissible virus that may cause less severe disease, and one that can be slowed — but not stopped — by today’s vaccines Read the Full Story |
|
Politics | | Kellogg's is facing increasing political pressure to resume contract talks with its 1,400 striking cereal plant workers.
Nebraska Gov. Pete Ricketts sent a letter to the company's CEO this week urging the company to return to the bargaining table with workers at its four plants nation... Read the Full Story |
|
Markets | |
When you have a precise retirement savings number you'd like to achieve, it takes dedication and consistent investing to get there.
Luckily, Americans have confidence that they'll achieve their retirement goals. Three in four workers (73%) believe they can fully retire with a comfortable lifestyl... Read the Full Story |
|
The Early Bird Stock Of The Day Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. | View Today's Stock Pick |
|